세계 G단백질 연결 수용체(GPCR) 시장 예측 : 제품 유형별, 분석 유형별, 용도별, 지역별 분석(-2030년)

According to Stratistics MRC, the Global G-Protein Coupled Receptors (GPCRs) Market is accounted for $3.70 billion in 2023 and is expected to reach $5.98 billion by 2030 growing at a CAGR of 7.1% during the forecast period. The diverse group of membrane receptors known as G-Protein Coupled Receptors (GPCRs), also referred to as seven-(pass)-trans membrane receptors. These can be found in the cell membrane and are in charge of interacting with external chemicals and relaying signals to intracellular molecules. GPCRs are cell surface receptors that function as an inbox for messages delivered as peptides, proteins, light energy, lipids, and sugars. These receptors are frequently employed in the management of a wide range of illnesses, including inflammatory disorders, metabolic disturbances, cardiac disorders, cancer, and monogenic disorders.

According to the American Heart Association's 2021 Journal, more than 130 million adults in the United States are expected to have some type of heart disease by 2035.

Market Dynamics:

Driver:

Increasing prevalence of chronic diseases

The increasing prevalence of chronic diseases serves as a robust driver in the G-Protein Coupled Receptors (GPCRs) market. GPCRs play a pivotal role in regulating numerous physiological processes, making them valuable drug targets. With a growing global burden of chronic conditions such as diabetes, cardiovascular diseases, and neurodegenerative disorders, the demand for pharmaceutical interventions that target GPCRs is on the rise. Researchers are exploring GPCRs for innovative therapeutic solutions, which has stimulated research and development in the pharmaceutical industry.

Restraint:

High cost of G-protein coupled receptors (GPCRs) cell lines

The high price of G-Protein Coupled Receptors (GPCRs) cell lines represents a significant restraint in the GPCR market. The substantial cost associated with acquiring these cell lines can be prohibitive for smaller research institutions and biotech startups, limiting their ability to engage in GPCR-related research and drug development. This pricing barrier can stifle innovation, reduce competition, and impede scientific progress in understanding and targeting GPCRs, potentially slowing down the discovery of new pharmaceuticals.

Opportunity:

Adoption of GPCRs in drug discovery across the world

The widespread adoption of G-Protein Coupled Receptors (GPCRs) in drug discovery represents a significant opportunity for the market. GPCRs are a diverse class of drug targets involved in regulating various physiological processes, making them crucial for pharmaceutical research. Their versatility and involvement in numerous diseases, including cancer, neurological disorders, and metabolic conditions, have led to increased interest. As drug discovery efforts become increasingly globalized, GPCRs offer a promising avenue for innovative drug development. This adoption of GPCRs as targets for new therapeutics enhances research and development initiatives, paving the way for novel medications, and underscores the substantial growth potential in the GPCR market on a global scale.

Threat:

Complexity of the GPCR signalling system

The family of cell surface receptors known as GPCRs includes many different types of receptors and has complex signaling systems. It can be difficult to comprehend how they interact with different ligands and downstream signaling cascades, which makes it more difficult to find new drugs and develop existing ones. Because of this complexity, it is harder to predict a drug candidate's effectiveness, and there is a higher risk of unanticipated negative effects. Additionally, a lot of research, cutting-edge technology, and collaboration are needed, which are expensive and time-consuming. All of these elements are expected to restrain market growth.

COVID-19 Impact:

The G-Protein Coupled Receptors (GPCR) market has been significantly impacted by the COVID-19 pandemic in a number of ways. Lab closures and resource redistribution towards pandemic-related studies resulted in a slowdown in the study of GPCRs, which are essential for drug discovery. On the other hand, it has hastened the adoption of computational and virtual screening techniques for GPCR drug development. Due to the role that GPCRs play in immune responses and the potential they provide for treating viral infections, the market saw an increase in demand for GPCR-targeted therapies. Overall, the pandemic affected the GPCR market by fostering innovation and stifling it with a move toward digital methods.

The cAMP functional assays segment is expected to be the largest during the forecast period

The cAMP functional assays segment is anticipated to register the largest market share in the anticipated timeframe. This is due to its critical role in drug discovery and understanding cellular signaling. cAMP assays are widely utilized for studying GPCR activation and signaling pathways, making them integral to identifying potential drug candidates. They enable researchers to assess GPCR responses to ligands, providing valuable insights into drug efficacy and safety. With the rising demand for GPCR-targeted drugs, cAMP assays have gained prominence, driving their dominance in the market.

The cancer research segment is expected to have the highest CAGR during the forecast period

The cancer research segment is experiencing the highest growth rate during the forecast period due to the pivotal role GPCRs play in cancer progression. Research has revealed GPCRs' involvement in tumor growth, angiogenesis, and metastasis, making them attractive targets for cancer therapy. Additionally, the market's growth is fueled by the increased emphasis on personalized medicine and the development of GPCR-targeted cancer drugs. Advances in understanding GPCR signaling in cancer have led to a surge in innovative therapies and a growing demand for GPCR-related research tools, positioning this segment for substantial expansion in the near future.

Region with largest share:

During the forecast period, North America is anticipated to witness largest market share, led by the economically and technologically developed nations of the United States, Canada, and Mexico. According to the American Cancer Society, there will be 1.9 million new cases of cancer and 609,360 cancer-related deaths in the United States alone in 2022. In a similar vein, the Canadian Cancer Statistics 2021 revealed that roughly 2 in 5 Canadians will receive a cancer diagnosis during their lifetime and that 1 in 4 will pass away from the disease. Further bolstering market growth in North America is the burden of chronic diseases, particularly in cardiovascular and cancer applications, which is raising demand for cutting-edge therapies and treatments.

Region with highest CAGR:

Asia-Pacific is expected to experience the highest growth during the forecast period due to the presence of a number of young businesses like NB Health Laboratory, HD Biosciences Co., Ltd., and Sosei Heptares. Regional growth is influenced by the number of initiatives companies take to enhance their market presence. Furthermore, regional expansion is also fueled by the growing prevalence of lifestyle disorders among the expanding populations of China, India, and other economies, as well as the need to treat them with receptors.

Key players in the market:

Some of the key players in G-Protein Coupled Receptors (GPCRs) market include: Abcam PLC, Accure Pharma, Actelion, Addex Pharmaceuticals Ltd, Arena Pharmaceuticals, Inc., BD (Becton, Dickinson and Company), BioInvenu, Inc., Cisbio Bioassays, Corning Incorporated, Enzo Life Sciences, Inc., Eurofins DiscoverX, HD Biosciences Co., Ltd, Merck Group, Molecular Devices, LLC., PerkinElmer Inc., Promega Corporation, Qiagen, Thermo Fisher Scientific WuXi AppTec and Confo Therapeutics.

Key Developments:

In March 2023, Confo Therapeutics, a leader in targeting G-Protein Coupled Receptors (GPCRs) (GPCRs), this week announced an agreement with Daiichi Sankyo for the discovery and development of small molecule agonists against an undisclosed CNS target. Confo will receive upfront and milestone payments totaling $183 million and tiered royalties on sales from any resulting products.

In December 2022, Sosei Group Corporation announced its partnership with Eli Lilly and Company, a global biopharmaceutical firm. The collaboration aims to facilitate drug discovery for novel G protein-coupled receptor (GPCR) targets linked to diabetes and metabolic diseases, including the development and commercialization of small molecules with therapeutic potential.

In April 2022, Ono Pharmaceutical Co., Ltd. signed a new collaboration agreement with Domain Therapeutics and Universite de Montreal to discover novel small molecules targeting G-Protein Coupled Receptors (GPCRs) (GPCRs) in a metabolic disease area.

Products Covered:

• Cell Culture Reagents
• Cell Lines
• Detection Kits
• Ligands

Assay Types Covered:

• cAMP Functional Assays
• Calcium Functional Assays
• Internalization Assays
• Radioligand Binding and GTPγS Functional Assays
• Trafficking Assays
• B-Arrestin Functional Assays
• Other Assay Types

Applications Covered:

• Cancer Research
• Cardiovascular Research
• Central Nervous System (CNS) Research
• Inflammation Research
• Metabolic Research
• Respiratory Research
• Other Applications

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Product Analysis
• 3.7 Application Analysis
• 3.8 Emerging Markets
• 3.9 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global G-Protein Coupled Receptors (GPCRs) Market, By Product

• 5.1 Introduction
• 5.2 Cell Culture Reagents
• 5.3 Cell Lines
• 5.4 Detection Kits
• 5.5 Ligands

6 Global G-Protein Coupled Receptors (GPCRs) Market, By Assay Type

• 6.1 Introduction
• 6.2 cAMP Functional Assays
• 6.3 Calcium Functional Assays
• 6.4 Internalization Assays
• 6.5 Radioligand Binding and GTPγS Functional Assays
• 6.6 Trafficking Assays
• 6.7 B-Arrestin Functional Assays
• 6.8 Other Assay Types

7 Global G-Protein Coupled Receptors (GPCRs) Market, By Application

• 7.1 Introduction
• 7.2 Cancer Research
• 7.3 Cardiovascular Research
• 7.4 Central Nervous System (CNS) Research
• 7.5 Inflammation Research
• 7.6 Metabolic Research
• 7.7 Respiratory Research
• 7.8 Other Applications

8 Global G-Protein Coupled Receptors (GPCRs) Market, By Geography

• 8.1 Introduction
• 8.2 North America
  • 8.2.1 US
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 Italy
  • 8.3.4 France
  • 8.3.5 Spain
  • 8.3.6 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 Japan
  • 8.4.2 China
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 New Zealand
  • 8.4.6 South Korea
  • 8.4.7 Rest of Asia Pacific
• 8.5 South America
  • 8.5.1 Argentina
  • 8.5.2 Brazil
  • 8.5.3 Chile
  • 8.5.4 Rest of South America
• 8.6 Middle East & Africa
  • 8.6.1 Saudi Arabia
  • 8.6.2 UAE
  • 8.6.3 Qatar
  • 8.6.4 South Africa
  • 8.6.5 Rest of Middle East & Africa

9 Key Developments

• 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 9.2 Acquisitions & Mergers
• 9.3 New Product Launch
• 9.4 Expansions
• 9.5 Other Key Strategies

10 Company Profiling

• 10.1 Abcam PLC
• 10.2 Accure Pharma
• 10.3 Actelion
• 10.4 Addex Pharmaceuticals Ltd
• 10.5 Arena Pharmaceuticals, Inc.
• 10.6 BD (Becton, Dickinson and Company)
• 10.7 BioInvenu, Inc.
• 10.8 Cisbio Bioassays
• 10.9 Corning Incorporated
• 10.10 Enzo Life Sciences, Inc.
• 10.11 Eurofins DiscoverX
• 10.12 HD Biosciences Co., Ltd
• 10.13 Merck Group
• 10.14 Molecular Devices, LLC.
• 10.15 PerkinElmer Inc.
• 10.16 Promega Corporation
• 10.17 Qiagen
• 10.18 Thermo Fisher Scientific
• 10.19 WuXi AppTec
• 10.20 Confo Therapeutics